Skip to main content
PMC home page
Oncotarget logoLink to Oncotarget
. 2017 Apr 5;8(24):39218–39229. doi: 10.18632/oncotarget.16836

The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages

Lingyan Ping 1,#, Ning Ding 1,#, Yunfei Shi 2, Lixia Feng 1, Jiao Li 1, Yalu Liu 1, Yufu Lin 1, Cunzhen Shi 1, Xing Wang 1, Zhengying Pan 3, Yuqin Song 1, Jun Zhu 1
PMCID: PMC5503608  PMID: 28424405

Abstract

The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has demonstrated promising efficacy in a variety of hematologic malignancies. However, the precise mechanism of action of the drug remains to be fully elucidated. Tumor-infiltrating macrophages presented in the tumor microenvironment have been shown to promote development and progression of B-cell lymphomas through crosstalk mediated by secreted cytokines and chemokines. Because Btk has been implicated in Toll-like receptor (TLR) signaling pathways that regulate macrophage activation and production of proinflammatory cytokines, we investigated the immunomodulatory effects of Btk inhibitor on macrophages. Our results demonstrate that Btk inhibition efficiently suppresses production of CXCL12, CXCL13, CCL19, and VEGF by macrophages. Furthermore, attenuated secretion of homeostatic chemokines from Btk inhibitor-treated macrophages significantly compromise adhesion, invasion, and migration of lymphoid malignant cells and even those not driven by Btk expression. The supernatants from Btk inhibitor-treated macrophages also impair the ability of endothelial cells to undergo angiogenic tube formation. Mechanistic analysis revealed that Btk inhibitors treatment downregulates secretion of homeostatic chemokines and cytokines through inactivation of Btk signaling and the downstream transcription factors, NF-κB, STAT3, and AP-1. Taken together, these results suggest that the encouraging therapeutic efficacy of Btk inhibitor may be due to both direct cytotoxic effects on malignant B cells and immunomodulatory effects on macrophages present in the tumor microenvironment. This novel mechanism of action suggests that, in addition to B-cell lymphomas, Btk inhibitor may also have therapeutic value in lymphatic malignancies and solid tumors lacking Btk expression.

Keywords: ibrutinib, Btk, immunomodulatory effect, macrophages

INTRODUCTION

B-cell lymphomas account for approximately 80% of all Non-Hodgkin's Lymphomas and encompass a variety of disease entities with distinct pathological characteristics, clinical features, and prognoses [1]. Gene profiling analysis has revealed that, in addition to neoplastic B cells, non-neoplastic immune cells present in the tumor microenvironment (TME) play an essential role in the biology of lymphoma and can serve as powerful predictors of disease outcomes [2]. The TME is comprised of many cell types, including macrophages, lymphocytes, stromal cells, fibroblasts, and the cells that make up the intratumoral vasculature. These cells promote development and progression of B-cell lymphomas through secretion of cytokines and chemokines that mediate crosstalk between malignant cells and immune cells [3]. For example, tumor-associated macrophages (TAMs) have been shown to secrete the homeostatic chemokines, CXCL12 and CXCL13, which bind to their respective G protein-coupled receptors on malignant B cells, CXCR4 and CXCR5. These interactions promote prosurvival signaling and protect malignant B cells from the cytotoxic effects of chemotherapies [4, 5]. In addition, Macrophage Inflammatory Protein-3 beta (MIP-3β), also called CCL19 is essential for the migration and spreading of mantle cell lymphoma [6]. Thus, TAMs presented in the TME represent a potential therapeutic target for treatment of B-cell lymphoma.

Bruton's tyrosine kinase (Btk) is a member of the Tec family of cytoplasmic tyrosine kinases, which are predominantly expressed in hematopoietic cells [7]. In addition to its essential regulatory role in B-cell proliferation and survival, Btk has also been implicated in promotion of Toll-like receptor (TLR) signaling [8], which regulates macrophage activation and production of proinflammatory cytokines. Several studies have demonstrated crosstalk between Btk and TLR signaling pathways to mediate transactivation of downstream cascades [9, 10]. Furthermore, macrophages from X-linked immunodeficient (xid) mice lacking Btk function exhibit impaired nitric oxide, TNF-α, and IL-1β production, suggesting that Btk plays a critical role in regulation of immunity [11, 12].

Ibrutinib, the first irreversible, small-molecule Btk inhibitor, has demonstrated promising therapeutic effects in patients with B-cell lymphoma [13, 14]. The encouraging clinical efficacy of ibrutinib has been reported to result not only from direct cytotoxic effects on malignant B cells, but also from anti-cancer mechanisms that diminish the contributions of the surrounding microenvironment to cancer cell growth and survival [15–17]. A majority of chronic lymphocytic leukemia and mantle cell lymphoma patients treated with ibrutinib display a transient increase in circulating lymphocytes and reduced lymphadenopathy. These observations are indicative of downregulation of BCR signaling in tumor cells, which leads to mobilization of malignant B cells from the tumor tissue to the peripheral bloodstream. Recently new generations of irreversible Btk inhibitors have exhibited different selectivity profile and more potent anti-tumor activity [18, 19]. Our developed inhibitor PLS-123 presents the dual-action inhibitory mode targeting both Btk catalytic activity and its own auto-activation [20, 21]. However, the precise mechanisms underlying effects of Btk inhibition on macrophages present in the TME are not well understood.

In this study, we report that the Btk inhibitors ibrutinib and PLS-123 exerted immunomodulatory effects through regulation of tumor-infiltrating macrophages and suppressed production of homeostatic chemokines and angiogenic cytokines. Thus, the promising therapeutic effects of Btk inhibition can be attributed to both direct inhibition of BCR signaling in lymphoma cells and immunomodulation of macrophages present in the TME.

RESULTS

Btk inhibition suppresses production of homeostatic chemokines and angiogenic cytokines by macrophages

To characterize the immunomodulatory effects of Btk inhibitors, THP-1 differentiated macrophages were pretreated with the Btk inhibitors ibrutinib and PLS-123 for 1 hour. After Btk inhibitor washout, the supernatants from lipopolysaccharide (LPS)-stimulated cells were analyzed by enzyme-linked immunosorbent assay (ELISA). Importantly, the Btk inhibitors ibrutinib and PLS-123 did not induce cytotoxic effects towards macrophages (Supplementary Figure 1). As shown in Figure 1A, Btk inhibition efficiently downregulated secretion of homeostatic chemokines (CXCL12, CXCL13, and CCL19), as well as the angiogenic cytokine, VEGF, in THP-1 differentiated macrophages. The similar results were also observed in human peripheral blood mononuclear cells (PBMCs; Figure 1B). To further determine whether downregulation occurred at the transcriptional level, total RNA was extracted from Btk inhibitor-treated THP-1 differentiated macrophages, and mRNA expression was analyzed by real-time polymerase chain reaction (PCR). Btk inhibition strongly reduced expression of the CXCL12, CXCL13, CCL19, and VEGF mRNAs, suggesting that Btk activation was required for transcription of these chemokines and this cytokine (Figure 1C).

Figure 1. Btk inhibition suppresses production of homeostatic chemokines and angiogenic cytokines by macrophages.

Figure 1

Open in a new tab

(A) THP-1 differentiated macrophages (2.5 × 105) were pretreated with indicated concentration of Btk inhibitors (0.2, 0.5, 1, 2, 5 μM) for 1 hour. (B) PBMCs (1 × 106) were pretreated with indicated concentration of Btk inhibitors (0.2, 1, 5 μM) for 1 hour. After Btk inhibitor washout, the cells were stimulated with LPS (1 μg/ml) for 17 hours and the culture supernatant was harvested for the analysis of the chemokines and cytokine production. (C) Total RNA was extracted, and the expression of mRNA was detected by real time PCR. *Significantly decreased compared to LPS treatment alone (p < 0.05). Results are representative of three similar experiments.

Depletion of Btk inhibits macrophage production of homeostatic chemokines and angiogenic cytokines

To further explore the role of Btk in macrophage signaling, the effects of Btk knockdown on chemokine and cytokine production was analyzed. Efficacy of siRNA-mediated knockdown of Btk was analyzed by Western blotting (Figure 2A). Macrophages transfected with Btk-specific siRNAs were stimulated with LPS for 18 hours [21], and levels of chemokines and cytokine in the supernatant were measured by ELISA. Btk knockdown significantly inhibited secretion of CXCL12, CXCL13, CCL19, and VEGF by macrophages (Figure 2B). Similarly, PCR analysis of siRNA-transfected macrophages demonstrated that loss of Btk expression blocked expression of homeostatic chemokines and the angiogenic cytokine at the transcriptional level (Figure 2C).

Figure 2. Depletion of Btk inhibits macrophage production of homeostatic chemokines and angiogenic cytokines.

Figure 2

Open in a new tab

(A & B) THP-1 differentiated macrophages were transfected with Btk siRNA for 48 hours and then stimulated with LPS (1 μg/ml) for 18 hours. The chemokine and cytokine production from macrophages were measured by ELISA. (C) Total RNA was extracted, and the expression of mRNA was detected by real time PCR. *Significantly decreased compared to LPS treatment alone (p < 0.05). Results are representative of three similar experiments.

Inhibition of Btk function in macrophages significantly compromises adhesion, invasion, and migration of lymphoid malignant cells

Tumor-infiltrated macrophages have been shown to promote progression of B-cell lymphomas through intercellular crosstalk mediated by cytokines and chemokines [3]. In addition, ibrutinib treatment has been demonstrated to efficiently inhibit adhesion and migration of malignant B cells through downregulation of chemokine-mediated Btk activation within tumor cells [17]. To investigate whether immunomodulatory effects of Btk inhibition on macrophages present in the TME affect tumor cell function, malignant B-cell lymphoma Namalwa and OCI-Ly7 cells were co-cultured with supernatants collected from control and Btk inhibitors-treated macrophages. Consistent with results showing that Btk inhibition decreases chemokines and cytokine production (Figure 1), adhesion of malignant B cells to fibronectin was attenuated by supernatant exposure in a dose-dependent manner (Figure 3A).

Figure 3. Inhibition of Btk function in macrophages significantly compromises adhesion, invasion, and migration of lymphoid malignant cells.

Figure 3

Open in a new tab

(A) Lymphoid malignant cells were subjected to adhesion assays in conditioned medium collected from control and Btk inhibitor-treated (0.2, 0.5, 1, 2, 5 μM) macrophages. The adherent cells were measured by CellTiter-Glo luminescent cell viability assay. (B & C) Migration and invasion of tumor cells were analyzed in transwell plates, and supernatant from macrophages was added into the lower chamber as a chemoattractant. *Significantly decreased compared to LPS treatment alone (p < 0.05). Results are representative of three similar experiments.

To further assess the impact of Btk inhibition of macrophages on tumor cell function, supernatant-treated Namalwa and OCI-Ly7 cells were subjected to an in vitro motility assay using a transwell culture system. Btk inhibitor-mediated decreases in chemokine and cytokine levels in macrophage supernatants were associated with concomitant decreases in the ability of malignant B cells treated with these supernatants to undergo invasion and migration. Even more importantly, the supernatants collected from Btk inhibitors-treated macrophages also strongly diminished the motility of T-cell lymphoma Hut78 cells, suggesting immunomodulatory effects of Btk inhibition on macrophages presented in the tumor microenvironment may also have therapeutic value in lymphatic malignancies not driven by Btk expression (Figure 3B and 3C; Supplementary Figure 2). Thus, in addition to their direct effects on tumor cells, Btk inhibitors likely also indirectly blocked the motility of neoplastic cells through downregulation of chemokine and cytokine production by macrophages.

Btk inhibition of macrophages affects endothelial cell tube formation

New growth of the vascular network plays an important role in progression of lymphoma and is dependent upon communication between various cell types present in the TME [22]. Thus, we hypothesized that treatment of macrophages with Btk inhibitors would compromise VEGF production and angiogenesis in the TME. A Matrigel assay revealed that treatment of endothelial cells with supernatants from control macrophages induced endothelial cell tube formation, while treatment with supernatants from Btk inhibitor-treated macrophages reduced tube formation in a dose-dependent manner (Figure 4). Thus, these results suggested that Btk may exert affects on angiogenesis through modulation of cytokine production by TAMs.

Figure 4. Btk inhibition of macrophages affects endothelial cell tube formation.

Figure 4

Open in a new tab

HUVEC cells were seeded into a Matrigel-coated plate and incubated with conditioned medium from macrophages for 20 hours. Tube-like structures of HUVECs formed were counted under a microscope. *Significantly decreased compared to LPS treatment alone (p < 0.05). Results are representative of three similar experiments.

Btk inhibition blocks activation of Btk and downstream signaling cascades

To investigate the mechanisms by which Btk inhibition blocks production of homeostatic chemokines and an angiogenic cytokine by macrophages, THP-1 differentiated macrophages were incubated with Btk inhibitors in the presence or absence of LPS stimulation. LPS stimulation is thought to mimic TLR/antigen interactions, thereby activating downstream signaling pathways [23]. Results from this analysis revealed that ibrutinib inhibited the LPS-induced Btk Tyr223 phosphorylation and the negative pathway feedback loop, resulting in amplified Tyr551 phosphorylation [24]. The dual-action Btk inhibitor PLS-123 not only significantly suppressed Btk Tyr223 phosphorylation but also reduced elevated Btk Tyr551 phosphorylation. Furthermore, Western blot analysis also demonstrated that Btk inhibition efficiently reduced downstream activation of PLCγ2 and MAPK family proteins (p38, ERK1/2 and JNK) [25], consistent with results showing that Btk inhibition downregulates chemokine and cytokine production. Interestingly, the phosphorylation of JNK was slightly upregulated by PLS-123 treatment (Figure 5).

Figure 5. Btk inhibition blocks activation of Btk and downstream signaling cascades.

Figure 5

Open in a new tab

THP-1 differentiated macrophages were pretreated with indicated concentration of Btk inhibitors for 1 hour and then stimulated or not with LPS (1 μg/ml) for 10 minutes. Whole cell extracts were probed by Western blot for Btk, PLCγ2, ERK, p38, and JNK. β-actin is shown as a loading control. Results are representative of three similar experiments.

Btk regulates homeostatic chemokine and angiogenic cytokine production through activation of NF-κB, STAT3, and AP-1

Because transcription factors are key regulators of chemokine and cytokine production, we next analyzed the effects of Btk inhibition on activation of NF-κB, STAT3, and AP-1 using a luciferase reporter assay in macrophages. Treatment with LPS resulted in significant increase in reporter activities associated with all three transcription factors. Reporter activity of NF-κB and AP-1 was strongly reduced by incubation with ibrutinib. The dual-action Btk inhibitor PLS-123 decreased the NF-κB and STAT3 activation. Similar to results from the reporter assay, the activation of transcription factor was also confirmed by Western blot analysis of nuclear extracts prepared from control and Btk inhibitor-treated macrophages (Figure 6). Consistent with previous immunoblotting result of JNK phosphorylation, the nuclear transcription factors AP-1 activation was slightly increased by PLS-123 treatment, which suggested its alternative mechanism of immunomodulatory effect towards macrophages. Together, these results suggested that Btk inhibition exerts anti-tumor immunomodulatory effects through the regulation of NF-κB, STAT3, and AP-1 activation in macrophages.

Figure 6. Btk regulates homeostatic chemokine and angiogenic cytokine production through activation of NF-κB, STAT3, and AP-1.

Figure 6

Open in a new tab

(A) THP-1 differentiated macrophages were transfected with NF-κB, STAT3 and AP-1 luciferase reporter constructs and then treated with indicated concentration of Btk inhibitor in the presence or absence of LPS stimulation (1 μg/ml) for 6 hours prior to the measurement of luciferase. (B) THP-1 differentiated macrophages were pretreated with the indicated concentrations of Btk inhibitors for 1 hour and then stimulated or not with LPS (1 μg/ml) for 10 minutes. The nuclear extracts of cultured cells were prepared and probed by Western blot analysis to measure p-p65, p-STAT3 and p-AP1 levels. PCNA is shown as a loading control. *Significantly decreased compared to LPS treatment alone (p < 0.05). Results are representative of three similar experiments.

DISCUSSION

Ibrutinib, the first selective, irreversible, small-molecule inhibitor of Btk, covalently binds with cysteine 481 (Cys-481) near the active site of the kinase to block its enzymatic activity [26]. Ibrutinib has clearly demonstrated promising therapeutic effects in clinical trials and has been approved by the Federal Drug Administration (FDA) for treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenström's macroglobulinemia. Importantly, the encouraging clinical efficacy of ibrutinib results from both direct cytotoxic effects on cancer cells, including activation of apoptosis, inhibition of DNA replication, and blockade of prosurvival signaling pathways, as well as from inhibition of interactions between tumor cells and the surrounding microenvironment that affect cellular adhesion and migration [27]. Recently, the immunomodulatory effect of ibrutinib has been reported to enhance the anti-tumor immune response of infiltrating T cells and reduce chronic graft-versus-host disease [28, 29]. Thus, these observations suggest that the effects of Btk inhibition on the TME require more detailed investigation.

Many lines of evidence indicate that the frequency and distribution of non-neoplastic immune cells in the TME is strongly associated with the outcome and prognosis of lymphoma [30]. TAMs promote tumor progression through secretion of homeostatic chemokines, pro-angiogenic factors, and suppressive cytokines, which limit the anticancer immune response [31]. Because Btk is expressed in macrophages and its phosphorylation is upregulated upon macrophage activation, we hypothesized that the promising anti-tumor activity of ibrutinib might be partially attributed to immunomodulatory effects on TAMs present in the TME. Understanding the complete mechanism of action of ibrutinib will help us to better explain the clinical findings associated with the drug, as well as identify potential new therapeutic uses.

Chang et al. previously demonstrated that B-cell lymphoma patients treated with ibrutinib display reduced lymphadenopathy, accompanied by transient increases in circulating malignant B cells in the peripheral bloodstream [17]. The underlying mechanism for this transient increase has been attributed to ibrutinib-mediated inhibition of chemokine-mediated adhesion and migration resulting from decreased stimulation of phosphorylated Btk (p-Btk) and phosphorylated PLC-γ2 (p-PLCγ2) by CXC12/CXCL13 in malignant B cells. However, results from our present study reveal that Btk inhibitors also exert immunomodulatory effects on macrophages that lead to decreased chemokines and cytokine production. Furthermore, supernatants collected from Btk inhibitors-treated macrophages efficiently compromise the adhesion, invasion and migration function in lymphoid malignancies and even those not driven by Btk expression. Thus, attenuated CXCL12, CXCL13, and CCL19 levels in the TME may limit the interactions between malignant cells and surrounding non-neoplastic immune cells, thereby contributing to mobilization of lymphoid malignant cells from tumor tissues to the peripheral bloodstream through a cancer cell-independent mechanism. This novel mechanism of action suggests that, in addition to B-cell lymphomas, Btk inhibitors may also displayed impressive therapeutic potency in lymphatic malignancies and solid tumors lacking Btk expression.

Tec family kinases, such as Btk, have been shown to activate downstream signaling pathways and transcription factors [32, 33]. Activation of the transcription factors NF-κB p65, STAT3, and AP-1 induces expression of genes responsible for inflammation, including CXCL12, CXCL13, CCL19, and VEGF, which play important roles in the TME [34–37]. Therefore, we investigated the transcriptional mechanisms underlying Btk inhibitor-mediated decreases in chemokine and cytokine production. Data from pharmacological studies and Western blot assays demonstrated that Btk inhibition reduced chemokine production through downregulation of Btk phosphorylation and activation of downstream transcription factors (Figures 5 and 6). These findings suggest that targeting Btk activation in TAMs could be an efficient therapeutic strategy that exerts anti-cancer effects through impacts on the TME.

Increasing evidences indicate that targeting TAMs present in the TME significantly reduces tumor progression and improves the efficacy of chemotherapy [38]. For example, the chemotherapeutic agent trabectedin exhibited remarkable anti-tumor activity resulting from cytotoxicity towards mononuclear phagocytes [39]. CSF-1R inhibitors represent a promising therapeutic approach for targeting TAMs. CSF-1/CSF-1R signaling has been shown to play essential roles in regulating differentiation and survival of macrophages and driving macrophage recruitment into tumor tissues [40, 41]. Results from a phase I clinical trial demonstrated that the CSF-1R-targeted monoclonal antibody RG7155 depleted CSF-1R+ CD163+ macrophages in tumor tissues and had significant clinical benefit in patients with diffuse-type giant cell tumors. Thus, chemo-immunomodulatory strategies targeting macrophages can successfully limit tumor progression and metastasis.

In conclusion, our results suggest that Btk inhibition modulates immune responses in the TME. These previously unrecognized immunomodulatory mechanisms associated with Btk inhibitors indicate that evaluation of this drug in other lymphatic malignancies and solid tumors, even those lacking Btk expression, may be warranted.

MATERIALS AND METHODS

Cell lines and culture conditions

The human acute monocytic leukemia cell line THP-1 and B-cell lymphoma cell line Namalwa and OCI-Ly7 were kindly provided by Dr. Fu (University of Nebraska Medical Center, Omaha, NE). The cutaneous T cell lymphoma cell line Hut78 were obtained from ATCC (Manassas, VA). All cells were grown in DMEM supplemented with 10% fetal bovine serum (FBS; Gibco, Life Technology, New Zealand), L-glutamine and penicillin-streptomycin in a humidified atmosphere of 5% CO2 at 37°C. The authentication of all cell lines was performed using short tandem repeat DNA fingerprinting analysis (Applied Biosystems, Foster City, CA). THP-1 monocytes were treated with 50 ng/ml of phorbol-12-myristate-13-acetate (PMA; Sigma-Aldrich, St. Louis, MO) for 48 hours to induce macrophage differentiation [42]. For conditioned medium generation, supernatants from THP-1 differentiated macrophages were collected, sterilized through a 0.22 μm filter, and kept at 4°C for further use. Human peripheral blood mononuclear cells (PBMCs) were freshly prepared from 20 ml of EDTA-blood from healthy volunteers. Cells were isolated using Lymphoprep (Axis Shield, Oslo, Norway) according to the protocol from the manufacture.

Reagents and antibodies

The Btk inhibitors ibrutinib and PLS-123 were synthesized at the laboratory of Dr. Zhengying Pan at Peking University Shenzhen Graduate School according to a previously published procedure [21, 26]. Antibodies against phospho-Tyr223-Btk (#5082), Btk (#8547), phospho-Tyr1217-PLCγ2 (#3871), PLCγ2 (#3872), phospho-p38 (#9211), p38 (#8690), phospho-ERK1/2 (#4370), ERK1/2(#9102), phosho-JNK (#9251) and JNK (#9252) were obtained from Cell Signaling Technology (Danvers, MA, USA). The anti-p65 (phospho S536), STAT3 (phospho Y705), AP-1 (phospho S63) and PCNA were purchased from Abcam (Cambridge, MA). The anti-phospho-Tyr551-Btk, β-actin (A5441) and Lipopolysaccharide (LPS) were obtained from BD Biosciences (San Jose, CA) and Sigma.

ELISA

THP-1 differentiated macrophages were treated with the indicated Btk inhibitors in the presence or absence of LPS stimulation, and supernatants were collected for the analysis of CXCL12, CXCL13, CCL19 and VEGF production by using ELISA kits (PeproTech, London, UK).

Real-time quantitative PCR

THP-1 differentiated macrophages were treated with Btk inhibitors in the presence or absence of LPS for 12 hours, and total RNA was extracted via RNA TRIzol Extraction (Life Technologies). The mRNA levels of CXCL12, CXCL13, CCL19, and VEGF were determined by SYBR real-time quantitative PCR kit. The primer sequences of the target genes are listed as follow: β-actin, 5′-CCTGGCACCCAGCACAAT-3′, and 5′-ATCAAGATCATTGCTCCTCCTGAGCGC-3′; CCL-12: 5′-TCCAAACTGTGCCCTTCA-3′, and 5′-AC TTTAGCTTCGGGTCAAT-3′, CCL-13: 5′-GCTCAG TCTTTATCCCTA-3′, and 5′-TTCTCAATACTTCCATC A-3′, CCL-19: 5′-GGCACCAATGATGCTGAA-3′, and 5′-CTCTGGATGATGCGTTCTAC-3′, VEGF: 5′-CTG GAGCGTGTACGTTGGT-3′, and 5′-TCGTTTAACTC AAGCTGCCTC-3′.

siRNA transfection

THP-1 differentiated macrophages were seeded on 24-well plates in complete media on the day of the transfection. siRNA oligonucleotides targeting Btk (1: 5′-GGCAGUAAGAAGGGUUCAATT-3′; 2: 5′-GU GAUCUGGUUCAGAAAUATT-3′) were synthesized by Invitrogen and transfected to cells using the Lipofectamine™ RNAiMAX reagent (Life Technologies). The efficiency of siRNA knockdown of target genes was determined by Western blotting.

Cell adhesion and motility assay

Lymphoid malignant cells were treated with the conditioned medium derived from macrophages for 3 hours, and then cells were seeded into 96-well plates that were precoated with fibronectin (BD Biosciences). Thirty minutes later cells were washed twice with PBS to remove the non-adherent cells, and adherent cells were measured by CellTiter-Glo luminescent cell viability assay kit. For relative adhesion determination, the group treated with LPS alone was set to be 1 and the other group was normalized to this group.

For cell invasion and migration assay, tumor cells suspended in serum free medium were pre-labeled with calcein-AM (Sigma) for 30 minutes, then cells were plated into FluoroBlok™ inserts (Corning), which were precoated with Fibronectin or not. The inserts were placed in a 24-well plate containing conditioned medium from macrophages. Twelve hours later, tumor cells in the lower chambers were measured by plate reader at bottom reading mode and visualized by an inverted fluorescence microscope (TCS-SP2, Leica Microsystems).

Tube formation assay

Growth factor-reduced Matrigel were distributed in 24-well plates and allowed to solidify at 37°C for at least 1 hour. HUVECs incubated in M199 containing 1% FBS for 6 hours were harvested after trypsin treatment and suspended in macrophage-derived conditioned medium. HUVECs were then seeded onto the solified Matrigel. After 20 hours, the cultures were observed and digital pictures were captured with phase contrast microscopy (Axio Observer A1, Zeiss). For relative tube formating determination, the group treated with LPS alone was set to be 1 and the other group was normalized to this group.

Western blotting

To prepare whole cell extracts, PMA-differentiated macrophages were lysed with RIPA lysis buffer [21]. Equivalent amounts of protein (10 μg) were resolved on SDS-PAGE gels, transferred and immobilized on nitrocellulose membranes (Amersham, Buckinghamshire, UK) and probed with the appropriate primary and secondary antibodies. Immunodetection was performed using a chemiluminescence detection system (Alpha Innotech, San Leandro, CA).

Transfection and luciferase reporter assay

THP-1 differentiated macrophages were transfected with the transfection reagent Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA) at 3 μl of reagent per microgram of DNA. Briefly, the NF-κB, STAT3 and AP-1 luciferase reporter plasmids were transfected to 90% confluent cells in 24-well culture plates. Eighteen hours after transfection, cells were treated with Btk inhibitor in presence or absence of LPS stimulation. After an additional 6 hours of incubation, cells were lyzed and luciferase activity was measured using Synergy 2 microplate reader (BioTek Instruments, Winooski, VT, USA).

Statistical analysis

All experiments were repeated more than three times and representative results are shown in the figures. Results are expressed as mean ± SD. Statistical analysis was performed using Student's t test. A confidence level of p < 0.05 was considered significant.

SUPPLEMENTARY FIGURES

Acknowledgments

This work was financially supported by NSFC (Nos. 81641011, 81470368, 81201873, and 81373270), Beijing Natural Science Foundation (Nos. 7152030, 7172047, and 7132050).

Abbreviations

BCR signal

B cell receptor signal

VEGF

vascular endothelial growth factor

JNK

c-Jun N-terminal protein kinase

ERK

extracellular-signal regulated kinases

PCNA

proliferating-cell-nuclear-antigen

NF-κB

nuclear factor ‘kappa-light-chain-enhancer' of activated B-cells

STAT3

signal transducer and activator of transcription 3

AP-1

activator protein 1

Itk

IL-2-inducible tyrosine kinase

CSF-1

colony stimulating factor-1

CSF-1R

CSF-1 receptor

MAPK

mitogen-activated protein kinases

Footnotes

CONFLICTS OF INTEREST

ZP received compensation and research funding from Beijing Reciproca Pharmaceuticals, Inc., who is developing PLS-123 series of compounds as anti-cancer drug.

REFERENCES

  • 1.Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011;117:5019–5032. doi: 10.1182/blood-2011-01-293050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Dave SS, Wright G, Tan B, Rosenwald A, Gascoyne RD, Chan WC, Fisher RI, Braziel RM, Rimsza LM, Grogan TM, Miller TP, LeBlanc M, Greiner TC, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159–2169. doi: 10.1056/NEJMoa041869. [DOI] [PubMed] [Google Scholar]
  • 3.Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol. 2011;29:1812–1826. doi: 10.1200/JCO.2010.32.8401. [DOI] [PubMed] [Google Scholar]
  • 4.Carlsen HS, Baekkevold ES, Morton HC, Haraldsen G, Brandtzaeg P. Monocyte-like and mature macrophages produce CXCL13 (B cell-attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis. Blood. 2004;104:3021–3027. doi: 10.1182/blood-2004-02-0701. [DOI] [PubMed] [Google Scholar]
  • 5.Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood. 2007;110:3316–3325. doi: 10.1182/blood-2007-05-089409. [DOI] [PubMed] [Google Scholar]
  • 6.Corcione A, Arduino N, Ferretti E, Raffaghello L, Roncella S, Rossi D, Fedeli F, Ottonello L, Trentin L, Dallegri F, Semenzato G, Pistoia V. CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells. Clin Cancer Res. 2004;10:964–971. doi: 10.1158/1078-0432.ccr-1182-3. [DOI] [PubMed] [Google Scholar]
  • 7.Mohamed AJ, Yu L, Backesjo CM, Vargas L, Faryal R, Aints A, Christensson B, Berglof A, Vihinen M, Nore BF, Smith CI. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev. 2009;228:58–73. doi: 10.1111/j.1600-065X.2008.00741.x. [DOI] [PubMed] [Google Scholar]
  • 8.Isaza-Correa JM, Liang Z, van den Berg A, Diepstra A, Visser L. Toll-like receptors in the pathogenesis of human B cell malignancies. J Hematol Oncol. 2014;7:57. doi: 10.1186/s13045-014-0057-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Doyle SL, Jefferies CA, O'Neill LA. Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFkappaB activation by lipopolysaccharide. J Biol Chem. 2005;280:23496–23501. doi: 10.1074/jbc.C500053200. [DOI] [PubMed] [Google Scholar]
  • 10.Doyle SL, Jefferies CA, Feighery C, O'Neill LA. Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase. J Biol Chem. 2007;282:36953–36960. doi: 10.1074/jbc.M707682200. [DOI] [PubMed] [Google Scholar]
  • 11.Mukhopadhyay S, George A, Bal V, Ravindran B, Rath S. Bruton's tyrosine kinase deficiency in macrophages inhibits nitric oxide generation leading to enhancement of IL-12 induction. J Immunol. 1999;163:1786–1792. [PubMed] [Google Scholar]
  • 12.Mukhopadhyay S, Mohanty M, Mangla A, George A, Bal V, Rath S, Ravindran B. Macrophage effector functions controlled by Bruton's tyrosine kinase are more crucial than the cytokine balance of T cell responses for microfilarial clearance. J Immunol. 2002;168:2914–2921. doi: 10.4049/jimmunol.168.6.2914. [DOI] [PubMed] [Google Scholar]
  • 13.Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42. doi: 10.1056/NEJMoa1215637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, Barrientos JC, Chmielowska E, Radford J, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–516. doi: 10.1056/NEJMoa1306220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood. 2012;119:1182–1189. doi: 10.1182/blood-2011-10-386417. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Tai YT, Chang BY, Kong SY, Fulciniti M, Yang G, Calle Y, Hu Y, Lin J, Zhao JJ, Cagnetta A, Cea M, Sellitto MA, Zhong MY, et al. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012;120:1877–1887. doi: 10.1182/blood-2011-12-396853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM, Kuil A, Herman SE, Chang S, Pals ST, Wilson W, Wiestner A, Spaargaren M, et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood. 2013;122:2412–2424. doi: 10.1182/blood-2013-02-482125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21. doi: 10.1186/s13045-016-0250-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9:80. doi: 10.1186/s13045-016-0313-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Li X, Zuo Y, Tang G, Wang Y, Zhou Y, Wang X, Guo T, Xia M, Ding N, Pan Z. Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014;57:5112–5128. doi: 10.1021/jm4017762. [DOI] [PubMed] [Google Scholar]
  • 21.Ding N, Li X, Shi Y, Ping L, Wu L, Fu K, Feng L, Zheng X, Song Y, Pan Z, Zhu J. Irreversible dual inhibitory mode: the novel Btk inhibitor PLS-123 demonstrates promising anti-tumor activity in human B-cell lymphoma. Oncotarget. 2015;6:15122–15136. doi: 10.18632/oncotarget.3824. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 2002;20:4368–4380. doi: 10.1200/JCO.2002.10.088. [DOI] [PubMed] [Google Scholar]
  • 23.Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, Takeda K, Akira S. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999;162:3749–3752. [PubMed] [Google Scholar]
  • 24.de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, Pals ST, Spaargaren M. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood. 2012;119:2590–2594. doi: 10.1182/blood-2011-11-390989. [DOI] [PubMed] [Google Scholar]
  • 25.Jefferies CA, O'Neill LA. Bruton's tyrosine kinase (Btk)– the critical tyrosine kinase in LPS signalling. Immunol Lett. 2004;92:15–22. doi: 10.1016/j.imlet.2003.11.017. [DOI] [PubMed] [Google Scholar]
  • 26.Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Mendonca RV, Sweeney MD, Scott KC, Grothaus PG, Jeffery DA, Spoerke JM, Honigberg LA, et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase. ChemMedChem. 2007;2:58–61. doi: 10.1002/cmdc.200600221. [DOI] [PubMed] [Google Scholar]
  • 27.Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood. 2011;117:6287–6296. doi: 10.1182/blood-2011-01-328484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A. 2015;112:E966–972. doi: 10.1073/pnas.1500712112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Schutt SD, Fu J, Nguyen H, Bastian D, Heinrichs J, Wu Y, Liu C, McDonald DG, Pidala J, Yu XZ. Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice. PLoS One. 2015;10:e0137641. doi: 10.1371/journal.pone.0137641. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014;105:1–8. doi: 10.1111/cas.12314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Ruffell B, Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462–472. doi: 10.1016/j.ccell.2015.02.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Petro JB, Khan WN. Phospholipase C-gamma 2 couples Bruton's tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes. J Biol Chem. 2001;276:1715–1719. doi: 10.1074/jbc.M009137200. [DOI] [PubMed] [Google Scholar]
  • 33.Hata D, Kitaura J, Hartman SE, Kawakami Y, Yokota T, Kawakami T. Bruton's tyrosine kinase-mediated interleukin-2 gene activation in mast cells. Dependence on the c-Jun N-terminal kinase activation pathway. J Biol Chem. 1998;273:10979–10987. doi: 10.1074/jbc.273.18.10979. [DOI] [PubMed] [Google Scholar]
  • 34.Pietila TE, Veckman V, Lehtonen A, Lin R, Hiscott J, Julkunen I. Multiple NF-kappaB and IFN regulatory factor family transcription factors regulate CCL19 gene expression in human monocyte-derived dendritic cells. J Immunol. 2007;178:253–261. doi: 10.4049/jimmunol.178.1.253. [DOI] [PubMed] [Google Scholar]
  • 35.Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010;21:11–19. doi: 10.1016/j.cytogfr.2009.11.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 2010;464:302–305. doi: 10.1038/nature08782. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Markovic J, Uskokovic A, Grdovic N, Dinic S, Mihailovic M, Jovanovic JA, Poznanovic G, Vidakovic M. Identification of transcription factors involved in the transcriptional regulation of the CXCL12 gene in rat pancreatic insulinoma Rin-5F cell line. Biochem Cell Biol. 2015;93:54–62. doi: 10.1139/bcb-2014-0104. [DOI] [PubMed] [Google Scholar]
  • 38.Ostuni R, Kratochvill F, Murray PJ, Natoli G. Macrophages and cancer: from mechanisms to therapeutic implications. Trends Immunol. 2015;36:229–239. doi: 10.1016/j.it.2015.02.004. [DOI] [PubMed] [Google Scholar]
  • 39.Germano G, Frapolli R, Belgiovine C, Anselmo A, Pesce S, Liguori M, Erba E, Uboldi S, Zucchetti M, Pasqualini F, Nebuloni M, van Rooijen N, Mortarini R, et al. Role of macrophage targeting in the antitumor activity of trabectedin. Cancer Cell. 2013;23:249–262. doi: 10.1016/j.ccr.2013.01.008. [DOI] [PubMed] [Google Scholar]
  • 40.Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25:846–859. doi: 10.1016/j.ccr.2014.05.016. [DOI] [PubMed] [Google Scholar]
  • 41.Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, Setty M, Leslie CS, Oei Y, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19:1264–1272. doi: 10.1038/nm.3337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Auwerx J. The human leukemia cell line, THP-1: a multifacetted model for the study of monocyte-macrophage differentiation. Experientia. 1991;47:22–31. doi: 10.1007/BF02041244. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

oncotarget-08-39218-s001.pdf (1.4MB, pdf)

Articles from Oncotarget are provided here courtesy of Impact Journals, LLC

RESOURCES